Inhibition of this tumor-associated immunosuppressive pathway by agents targeted to PD-1 or its ligand PD-L1, was shown to restore functional antitumor immune responses in experimental tumor models and in treated patients [2, 3, 31]. This evidence concerns the gene CD274 and neoplasm.